Open Access Could Transform Drug Discovery: A Case Study of JQ1

被引:18
作者
Arshad, Zeeshaan [1 ,2 ]
Smith, James [3 ,4 ]
Roberts, Mackenna [4 ]
Lee, Wen Hwa [1 ]
Davies, Ben [3 ,4 ]
Bure, Kim [5 ]
Hollander, Georg A. [6 ,7 ,8 ]
Dopson, Sue [9 ]
Bountra, Chas [1 ]
Brindley, David [3 ,4 ,9 ,10 ,11 ,12 ]
机构
[1] Univ Oxford, Nuffield Dept Med, Struct Genom Consortium, Oxford, England
[2] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland
[3] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England
[4] Univ Oxford, Oxford UCL Ctr Adv Sustainable Med Innovat CASMI, Oxford, England
[5] Sartorius Stedim, Gottingen, Germany
[6] Univ Basel, Dept Biomed, Basel, Switzerland
[7] Basel Univ Childrens Hosp, Basel, Switzerland
[8] Univ Oxford, Dept Pediat, Oxford, England
[9] Univ Oxford, Said Business Sch, Oxford, England
[10] UCL, UCL Sch Pharm, Ctr Behav Med, London, England
[11] Harvard Stem Cell Inst, Cambridge, MA USA
[12] USCF Stanford Ctr Excellence Regulatory Sci & Inn, San Francisco, CA USA
关键词
Epigenetics; Open Innovation; Healthcare Translation; SGC (Structural Genomics Consortium); Bromodomain; Drug Discovery; JQ1; Open Access; OPEN INNOVATION; ALZHEIMERS-DISEASE; ATTRITION; CANDIDATES; MALARIA; IMPACT;
D O I
10.1517/17460441.2016.1144587
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of drug candidates and the lengthy transition times during development. Open access is an emerging model of open innovation that places no restriction on the use of information and has the potential to accelerate the development of new drugs. Areas Covered: To date, no quantitative assessment has yet taken place to determine the effects and viability of open access on the process of drug translation. This need is addressed within this study. The literature and intellectual property landscapes of the drug candidate JQ1, which was made available on an open access basis when discovered, and conventionally developed equivalents that were not are compared using the Web of Science and Thomson Innovation software, respectively. Expert opinion: Results demonstrate that openly sharing the JQ1 molecule led to a greater uptake by a wider and more multi-disciplinary research community. A comparative analysis of the patent landscapes for each candidate also found that the broader scientific diaspora of the publically released JQ1 data enhanced innovation, evidenced by a greater number of downstream patents filed in relation to JQ1. The authors' findings counter the notion that open access drug discovery would leak commercial intellectual property. On the contrary, JQ1 serves as a test case to evidence that open access drug discovery can be an economic model that potentially improves efficiency and cost of drug discovery and its subsequent commercialization.
引用
收藏
页码:321 / 332
页数:12
相关论文
共 55 条
  • [1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
    Abboud, Camille
    Berman, Ellin
    Cohen, Adam
    Cortes, Jorge
    DeAngelo, Daniel
    Deininger, Michael
    Devine, Steven
    Druker, Brian
    Fathi, Amir
    Jabbour, Elias
    Jagasia, Madan
    Kantarjian, Hagop
    Khoury, Jean
    Laneuville, Pierre
    Larson, Richard
    Lipton, Jeffrey
    Moore, Joseph O.
    Mughal, Tariq
    O'Brien, Susan
    Pinilla-Ibarz, Javier
    Quintas-Cardama, Alfonso
    Radich, Jerald
    Reddy, Vishnu
    Schiffer, Charles
    Shah, Neil
    Shami, Paul
    Silver, Richard T.
    Snyder, David
    Stone, Richard
    Talpaz, Moshe
    Tefferi, Ayalew
    Van Etten, Richard A.
    Wetzler, Meir
    Abruzzese, Elisabetta
    Apperley, Jane
    Breccia, Massimo
    Byrne, Jenny
    Cervantes, Francisco
    Chelysheva, Ekaterina
    Clark, R. E.
    de Lavallade, Hugues
    Dyagil, Iryna
    Gambacorti-Passerini, Carlo
    Goldman, John
    Haznedaroglu, Ibrahim
    Hjorth-Hansen, Henrik
    Holyoake, Tessa
    Huntly, Brian
    le Coutre, Philipp
    Lomaia, Elza
    [J]. BLOOD, 2013, 121 (22) : 4439 - 4442
  • [2] Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry
    Anand, R
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 : S33 - S39
  • [3] Harnessing open innovation
    不详
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (05) : 344 - 345
  • [4] Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
    Bowes, Joanne
    Brown, Andrew J.
    Hamon, Jacques
    Jarolimek, Wolfgang
    Sridhar, Arun
    Waldron, Gareth
    Whitebread, Steven
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 909 - 922
  • [5] Investors unfazed by drug-patent expiry
    Brindley, David
    Reeve, Brock
    Mason, Chris
    [J]. NATURE, 2012, 481 (7381) : 265 - 265
  • [6] Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
    Brookmeyer, R
    Gray, S
    Kawas, C
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) : 1337 - 1342
  • [7] Getting pharmaceutical R&D back on target
    Bunnage, Mark E.
    [J]. NATURE CHEMICAL BIOLOGY, 2011, 7 (06) : 335 - 339
  • [8] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
    Capdeville, R
    Buchdunger, E
    Zimmermann, J
    Matter, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) : 493 - 502
  • [9] Beyond high tech: early adopters of open innovation in other industries
    Chesbrough, H
    Crowther, AK
    [J]. R & D MANAGEMENT, 2006, 36 (03) : 229 - 236
  • [10] The logic of open innovation: Managing intellectual property
    Chesbrough, H
    [J]. CALIFORNIA MANAGEMENT REVIEW, 2003, 45 (03) : 33 - +